Express News | Cytosorbents Announces Launch and Immediate Availability of Purifi™ Blood Pump in European Union
Here's Why Shareholders Should Examine Cytosorbents Corporation's (NASDAQ:CTSO) CEO Compensation Package More Closely
B. Riley Securities Reiterates Buy on CytoSorbents, Maintains $3 Price Target
B. Riley Securities analyst Yuan Zhi reiterates CytoSorbents (NASDAQ:CTSO) with a Buy and maintains $3 price target.
Cytosorbents First Quarter 2024 Earnings: In Line With Expectations
Earnings Call Summary | Cytosorbents(CTSO.US) Q1 2024 Earnings Conference
The following is a summary of the Cytosorbents Corporation (CTSO) Q1 2024 Earnings Call Transcript:Financial Performance:Cytosorbents Corporation experienced a 14% increase in product sales in Q1 2024
CytoSorbents Q1 2024 GAAP EPS $(0.12), Inline, Sales $9.787M Beat $9.785M Estimate
CytoSorbents (NASDAQ:CTSO) reported quarterly losses of $(0.12) per share which met the analyst consensus estimate. This is a 29.41 percent increase over losses of $(0.17) per share from the same peri
Cytosorbents | 10-Q: Quarterly report
CytoSorbents: Q1 Earnings Snapshot
Earnings Flash (CTSO) CYTOSORBENTS Posts Q1 Revenue $9.8M, Vs. Street Est of $9.79M
04:18 PM EDT, 05/09/2024 (MT Newswires) -- Earnings Flash (CTSO) CYTOSORBENTS Posts Q1 Revenue $9.8M, vs. Street Est of $9.79M
Express News | Cytosorbents Q1 EPS USD -0.12
Express News | Cytosorbents Q1 Product Gross Margin 76%
Express News | Cytosorbents Q1 Revenue USD 8.965 Million
Express News | Cytosorbents Reports First Quarter 2024 Results
Cytosorbents 1Q Loss $6.36M >CTSO
Cytosorbents 1Q Loss $6.36M >CTSO
Cytosorbents 1Q Rev $9.79M >CTSO
Cytosorbents 1Q Rev $9.79M >CTSO
Hold Rating on Cytosorbents Amid Regulatory Uncertainties and Mixed Clinical Results
CytoSorbents Executives Take Pay Cuts for Stock Options
Cytosorbents Full Year 2023 Earnings: Misses Expectations
Cytosorbents Corporation (NASDAQ:CTSO) Q4 2023 Earnings Call Transcript
HC Wainwright & Co. Reiterates Neutral on CytoSorbents, Maintains $1 Price Target
HC Wainwright & Co. analyst Sean Lee reiterates CytoSorbents with a Neutral and maintains $1 price target.
No Data